AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Xenon Pharmaceuticals Inc.
Video analysis: XENE
All videosNo video analysis for this stock yet. Request one from our team.
News: XENE
Xenon to Present at Wells Fargo Healthcare Conference
VANCOUVER, BC and BOSTON, MA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference:
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, BC and BOSTON, MA, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to five new non-officer employees consisting of an aggregate of 13,450 share options and 7,850 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company's Board of Directors with an effective date of August 27, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
VANCOUVER, BC and BOSTON, MA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced multiple data presentations at the upcoming 16th European Epilepsy Congress (EEC), taking place September 5-9, 2026, in Athens, Greece.
BlackRock Inc. Invests $454.06 Million in Xenon Pharmaceuticals Inc. $XENE
BlackRock Inc. bought a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ: XENE) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 7,522,482 shares of the biopharmaceutical company's stock, valued at approximately $454,057,000. BlackRock Inc. owned about 7.78% of Xenon Pharmaceuticals
Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity
Xenon Pharmaceuticals (XENE) is upgraded to "Strong Buy" following positive phase 3 X-TOLE2 results for azetukalner in focal onset seizures [FOS]. Company plans NDA filing for azetukalner in FOS in Q3 2026, with X-TOLE3 supporting potential ex-US expansion. Major depressive disorder [MDD] is a key pipeline focus, with phase 3 X-NOVA2 topline data expected in 1H 2027.
Xenon Pharmaceuticals Q2 Earnings Call Highlights
10x Genomics reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara Bio. Excluding non-recurring settlement revenue in both periods, revenue was $149.4 million, up 3% from the prior-year quarter.
XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus
Xenon posts a narrower-than-expected Q2 loss as azetukalner advances toward a planned FDA filing, while its cash runway is expected to support operations into 2029.
Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript
